🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

U.S. may cut some Moderna vaccine doses in half to speed rollout, official says

Published 01/03/2021, 04:20 PM
Updated 01/03/2021, 04:25 PM
© Reuters.
PFE
-
MRNA
-

By Brendan Pierson

(Reuters) - The U.S. government is considering giving some people half the dose of Moderna (NASDAQ:MRNA)'s COVID-19 vaccine in order to speed vaccinations, a federal official said on Sunday.

Moncef Slaoui, head of Operation Warp Speed, the federal vaccine program, said on CBS' "Face the Nation" that officials were in talks with Moderna and the Food and Drug Administration about the idea. Moderna's vaccine requires two injections.

"We know that for the Moderna vaccine, giving half of the dose to people between the ages of 18 and 55, two doses, half the dose, which means exactly achieving the objective of immunizing double the number of people with the doses we have," Slaoui said.

"We know it induces identical immune response" to the full dose, he added.

Moderna and the FDA could not immediately be reached for comment.

The U.S. Centers for Disease Control and Prevention said it had administered 4,225,756 first doses of COVID-19 vaccines in the country as of Saturday morning and distributed 13,071,925 doses.

The U.S. has also approved a vaccine from Pfizer (NYSE:PFE), which like Moderna's requires two shots. Vaccinations have fallen far short of early targets, as officials had hoped to have 20 million people vaccinated by the end of the 2020.

Slaoui said he was optimistic vaccinations would continue to accelerate. He rejected the suggestion that officials should prioritize giving more people a single shot, rather than holding back doses for the second shot, saying that cutting Moderna vaccine doses in half was "a more responsible approach that would be based on facts and data."

Slaoui said it would likely not be known until late spring whether vaccinated people can still spread the disease to others.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.